Update on the Role of Candesartan in the Optimal Management of Hypertension and Cardiovascular Risk Reduction

Integrated Blood Pressure Control - New Zealand
doi 10.2147/ibpc.s9963
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Informa UK Limited

Related search

Update on the Clinical Pharmacology of Candesartan Cilexetil

American Journal of Hypertension
Internal Medicine
2000English

Cardiovascular and Coronary Risk Estimation in Hypertension Management

Heart
2002English

Extent of Cardiovascular Risk Reduction Associated With Treatment of Isolated Systolic Hypertension

Archives of Internal Medicine
2003English

Dietary Strategies for the Management of Cardiovascular Risk: Role of Dietary Carbohydrates

Proceedings of the Nutrition Society
MedicineNutritionDietetics
2014English

Management of Patients With Uncontrolled Arterial Hypertension – The Role of Electronic Compliance Monitoring, 24-H Ambulatory Blood Pressure Monitoring and Candesartan/HCT

BMC Cardiovascular Disorders
Cardiovascular MedicineCardiology
2006English

Role of Coronary Artery Calcium for Stratifying Cardiovascular Risk in Adults With Hypertension

Hypertension
Internal Medicine
2019English

Optimal Management of Hypertension in Elderly Patients

Integrated Blood Pressure Control
Internal MedicineCardiovascular MedicineCardiology
2010English

Benefit Risk Assessment and Update on the Use of Docetaxel in the Management of Breast Cancer

Cancer Management and Research
Oncology
2013English

An Update on the Management of Low Risk Differentiated Thyroid Cancer

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy